QUERCETIN AND CURCUMIN AS POTENTIALLY POWERFUL "PRIOLOID" THERAPEUTICS
Quercetin turns fibrils into protease-sensitive, structurally loose and non-cytotoxic forms
Please note in the above image Curcumin’s effect on fibril formation.
I have been searching for answers to the systemic amyloidosis and anchorless prion pathologies of the Spike Protein. I believe Quercetin could prove to be a very powerful therapeutic in combatting these pathological mechanisms.
What I find most interesting about Quercetin is that it breaks apart prion fibril formations. One wonders if this could potentially prevent or remedy the fibril aggregates being found by embalmers. Please note, I do not believe the fibril aggregates are any sort of “nanotechnology.” I believe they are rapidly induced and developing “prioloid” aggregates.
Some highlights regarding Quercetin and amyloids:
• Quercetin binding to prion protein is determined, and the network of the binding site at the molecular level is visualized.
• In contrast to conventional studies of amyloidogenic drugs, quercetin accelerates fibrillation of prion protein. (A GOOD thing.)
• Quercetin turns fibrils into protease-sensitive, structurally loose and non-cytotoxic forms.
• Quercetin shows its uniqueness from typical antiamyloidogenic drugs.
• Quercetin treatment can disaggregate moPrP (mouse prion) fibrils and lead to the formation of the proteinase-sensitive amorphous aggregates. Furthermore, quercetin-bound fibrils can reduce the membrane disruption of erythrocytes.
• Quercetin is distinct from the typical function of antiamyloidogenic drugs that inhibit the formation of amyloid fibrils.
Curcumin may be a powerful alloy and “wing man” to Quercetin.
• Curcumin alone reduced prion fibril formation significantly.
• Curcumin effectively rescues the cells from apoptosis and decreases the ROS level caused by subsequent co-incubation with prion amyloid fibrils.
I believe urgent clinical trials are needed to assess the efficacy of Quercetin and Curcumin as prophylaxis, and treatment of both Acute and Long COVID.